Pd0-mediated rapid coupling between methyl iodide and heteroarylstannanes: an efficient and general method for the incorporation of a positron-emitting11C radionuclide into heteroaromatic frameworks

Chemistry - A European Journal

Volumn 15, Issue 45, 2009, Pages 12489-12495

  Suzuki, Masaaki ^a,b   Sumi, Kengo ^b   Koyama, Hiroko ^b   Siqin, ^b   Hosoya, Takamitsu ^b   Takashima Hirano, Misato ^a   Doi, Hisashi ^a  

^a RIKEN   (Japan)

^b GIFU UNIVERSITY   (Japan)

Author keywords

C C coupling; Heterocycles; Isotopic labeling; Palladium; Tin

Indexed keywords

C-C COUPLING; CARBON FRAMEWORK; DMF SOLVENTS; GENERAL APPROACH; GENERAL METHOD; HETEROAROMATIC COMPOUNDS; HETEROCYCLES; ISOTOPIC LABELING; LOW-YIELD; METHYL GROUP; METHYL IODIDE; PET TRACER; PHOSPHINE LIGANDS; REACTIVE SUBSTRATES; VITAL SYSTEMS;

FLUORINE CONTAINING POLYMERS; HYDROCARBONS; ISOTOPES; LABELING; ORGANIC SOLVENTS; PALLADIUM; PHOSPHORUS COMPOUNDS; POSITRONS; RADIOISOTOPES; TIN;

POSITRON EMISSION TOMOGRAPHY;

CARBON; HETEROCYCLIC COMPOUND; IODINATED HYDROCARBON; LIGAND; METHYL IODIDE; ORGANOMETALLIC COMPOUND; PALLADIUM; RADIOISOTOPE; TIN; TRI N BUTYL(2 THIENYL)STANNANE; TRI-N-BUTYL(2-THIENYL)STANNANE;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; ISOTOPE LABELING; POSITRON EMISSION TOMOGRAPHY;

CARBON RADIOISOTOPES; HETEROCYCLIC COMPOUNDS; HYDROCARBONS, IODINATED; ISOTOPE LABELING; LIGANDS; MOLECULAR STRUCTURE; ORGANOMETALLIC COMPOUNDS; PALLADIUM; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; TIN;

EID: 70849085211     PISSN: 09476539     EISSN: 15213765     Source Type: Journal    
DOI: 10.1002/chem.200901145     Document Type: Article

References (64)

1. Parts 1-8: a) M. Suzuki, H. Doi, M. Björkman, Y. Andersson, B. Lângstrom, Y. Watanabe, R. Noyori, Chem. Eur. J. 1997, 3, 2039-2042;
2. b) M. Suzuki, R. Noyori, B. Långström, Y. Watanabe, Bull. Chem. Soc. Jpn. 2000, 73, 1053-1070;
3. c) M. Suzuki, H. Doi, K. Kato, M. Björkman, B. Långström, Y. Watanabe, R. Noyori, Tetrahedron 2000, 56, 8263-8273;
4. d) M. Björkman, H. Doi, B. Resul, M. Suzuki, R. Noyori, Y. Watanabe, B. Långström, J. Labelled Compd. Radiopharm. 2000, 43, 1327-1334;
5. e) T. Hosoya, M. Wakao, Y. Kondo, H. Doi, M. Suzuki, Org. Biomol. Chem. 2004, 2, 24-27;
6. f) M. Suzuki, H. Doi, T. Hosoya, B. Långström, Y. Watanabe, TrAC Trends Anal. Chem. 2004, 23, 595-607;
7. g) T. Hosoya, K. Sumi, H. Doi, M. Wakao, M. Suzuki, Org. Biomol. Chem. 2006, 4, 410-415;
8. Patent: M. Suzuki, T. Hosoya, JP 2005-306670, 2005;
9. M. Suzuki, T. Hosoya, PCT/JP2006/320104, 2006;
10. M. Suzuki, T. Hosoya, WO/2007/046258;
11. h) rapid C-methylation using a boronic acid ester as the trapping agent: M. Suzuki, H. Doi, H. Tsukada, JP 2006-229169, 2006;
12. M. Suzuki, H. Doi, H. Tsukada, PCT/JP2007/066411, 2007;
13. M. Suzuki, H. Doi, H. Tsukada, WO/2008/023780, 2008;
14. H. Doi, I. Ban, A. Nonoyama, K. Sumi, C. Kuang, T. Hosoya, H. Tsukada, M. Suzuki, Chem. Eur. J. 2009, 15, 4165-4171; see also the application by other groups based on our method:
15. 11C-methyl]MADAM: J. Tarkiainen, J. Vercouillie, P. Emond, J. Sandell, J. Hiltunen, Y. Frangin, D. Guilloteau, C. Halldin, J. Labelled Compd. Radiopharm. 2001, 44, 1013-1023;
16. 11C]toluene: M. Gerasimov, J. Logan, R. A. Ferrieri, R. D. Muller, D. Alexoff, S. L. Dewey, Nucl. Med. Biol. 2002, 29, 607-612, and references therein;
17. 11C]methyl-6-nitroquipazine: J. Sandell, M. Yu, P. Emond, L. Garreau, S. Chalon, K. Någren, D. Guilloteau, C. Halldin, Bioorg. Med. Chem. Lett. 2002, 12, 3611-3613, and references therein;
18. 11C-labelled Citalopram analogue: J. Madsen, P. Merachtsaki, P. Davoodpour, M. Bergström, B. Långström, K. Andersen, C. Thomsen, L. Martiny, G. M. Knudsen, Bioorg. Med. Chem. 2003, 11, 3447-3456;
19. 11C]5MA for imaging of brain nicotinic acetylcholine receptors: Y. lida, M. Ogawa, M. Ueda, A. Tominaga, H. Kawashima, Y. Magata, S. Nishiyama, H. Tsukada, T. Mukai, H. Saji, J. Nucl. Med. 2004, 45, 878-884;
20. 11C]methylation, see:
21. o) O. Langer, T. Forngren, J. Sandell, F. Dolle, B. Långström, K. Någren, C. Halldin, J. Labelled Compd. Radiopharm. 2003, 46, 55-65;
22. p) L. Samuelsson, B. Långström, J. Labelled Compd Radiopharm. 2003, 46, 263-272;
23. 11C]methyl-6-quinolinyl)(cis-4- methoxycyclohexyl)methanone for imaging of the metabotropic glutamate 1 receptor: Y. Huang, R. Narendran, F. Bischoff, N. Guo, Z. Zhu, S.-A Bae, A. S. Lesage, M. Laruelle, J. Med. Chem. 2005, 48, 5096-5099;
24. r) J. Toyohara, K. Kumata, K. Fukushi, T. Irie, K. Suzuki, J. Nucl. Med. 2006, 47, 1717-1722;
25. s) I. Bennacef, C. Perrio, M.-C. Lasne, L. Barré, J. Org. Chem. 2007, 72, 2161-2165; for the use of functional organostannanes, see:
26. t) T. Bourdier, M. Huiban, A. Huet, F. Sobrio, E. Fouquet, C. Perrio, L. Barré, Synthesis 2008, 978-984;
27. u) M. Huiban, A. Huet, L. Barré, F. Sobrio, E. Fouquet, C. Perrio, Chem. Commun. 2006, 97-99;
28. T. Forngren, L. Samuelsson, B. Långström, J. Labelled Compd Radiopharm. 2004, 47, 71-78.
29. a) J. S. Fowler, A. P. Wolf, J. R. Barrio, J. C. Mazziotta, M. E. Phelps in Positron Emission Tomography and Autoradiography (Eds.: M. E. Phelps, J. C. Mazziotta, H. R. Schelbert), Raven Press, New York, 1986, Chapter 9-11;
30. b) B. Långstrom, R. E. Dannais in Principle of Nuclear Medicine, 2nd ed. (Eds.: H. N. Wagner, Z. Szabo, J. W. Buchanan, W. B. Saunders), Publishing, Philadelphia, 1995, Section 1, Chapter 11;
31. c) J. S. Fowler, A. P. Wolf, Acc. Chem. Res. 1997, 30, 181-188.
32. a) G. Lappin, R. C. Garner, Nat. Rev. Drug Discovery 2003, 2, 233-240;
33. b) M. Bergström, A. Grannen, B. Långstrom, Eur. J. Clin. Phar macol. 2003, 59, 357-366;
34. c) The European Medicines Agency, Evaluation of Medicines for Human Use (EMEA), Position paper on non-clinical safety studies to support clinical trials with a single microdose, CPMP/SWP/2599/02/Rev1, 23 June 2004;
35. d) U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Guidance for Industry, Investigators, and Reviewers, Exploratory IND Studies, January 2006;
36. e) Japan's response to microdosing study, Notification No. 0603001, 3 June 2008, Guidance for the Conduct of Microdoing Clinical Trials, Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare, Japan.
37. C. M. L. West, T. Jones, P. Price, Nat. Rev. Cancer 2004, 4, 457-469.
38. a) R. A. Ferrieri, A. P. Wolf, Radiochim. Acta 1983, 34, 69-83;
39. b) B. Långström, G. Antoni, P. Gullberg, C. Halldin, P. Malmborg, K. Någren, A. Rimland, H. Svärd, J. Nucl. Med. 1987, 28, 1037-1040;
40. c) G. Antoni, T. Kihlberg, B. Långström in Handbook of Radiopharmaceuticals (Eds.: M. J. Welch, C. S. Redvanl), Wiley, New York, 2003, pp. 141-194.
41. 11C] methylated product from the large amount of remaining unreactive halide substrate, see ref. [1t-v].
42. a) M. Suzuki, K. Kato, R. Noyori, Yu. Watanabe, H. Takechi, K. Matsumura, B. Långström, Y. Watanabe, Angew. Chem. 1996, 108, 366-369;
43. Angew. Chem. Int. Ed. Engl. 1996, 35, 334-336;
44. b) H. Takechi, K. Matsumura, Yu. Watanabe, K. Kato, R. Noyori, M. Suzuki, Y. Watanabe, J. Biol. Chem. 1996, 271, 5901-5906;
45. c) M. Björkman, Y. Andersson, H. Doi, K. Kato, M. Suzuki, R. Noyori, Y. Watanabe, B. Långström, Ada Chem. Scand. 1998, 52, 635-640;
46. d) Yu. Watanabe, K. Matsumura, H. Takechi, K. Kato, H. Morii, M. Björkman, B. Långström, R. Noyori, M. Suzuki, Y. Watanabe, J. Neurochem. 1999, 72, 2583-2592;
47. e) R. Noyori, Angew. Chem. 2002, 114, 2108-2123;
48. Angew. Chem. Int. Ed. 2002, 41, 2008-2022.
49. 3I) with a large amount (mg) of a reacting substrate. Therefore, we performed the reaction by using an excess amount of an alkenylstannane with the methyl iodide.
50. 2]- catalyzed Stille reaction in the presence of CsF, see: a) A. F. Littke, L. Schwarz, G. C. Fu, J. Am. Chem. Soc. 2002, 124, 6343-6348; see also the iron-catalyzed alkenylation of organomagnesium compounds:
51. b) G. Cahiez, H. Avedissian, Synthesis 1998, 1199-1205; and the palladium-catalyzed arylation with aryl chlorides:
52. c) H. A. Chiong, O. Daugulis, Org. Lett. 2007, 9, 1449-1451;
53. [1e]
54. Pyridine formed by destannylation was not observed by GC analysis.
55. F. Paul, J. Patt, J. F. Hartwig, Organometallics 1995, 14, 3030-3039.
56. Phosphine was limited to 16 equiv in the small-scale synthesis of the PET tracers due to its limited solubility. Thus, the conditions defined by the use of NMP as solvent and an increased ratio of the phosphine ligand are highly tolerant and could be applied to some improved conditions in actual PET tracer synthesis, as long as such required two factors are not changed.
57. [1h] are much better precursors for PET tracer synthesis.
58. a) R. C. Garner, Current Drug Metab. 2000, 1, 205-213;
59. b) G. Lappin, R. C. Garner, Anal. Bioanal. Chem. 2004, 378, 356-364.
60. a) M. Bergström, A. Grannén, B. Långström, Eur. J. Clin. Pharmacol. 2003, 59, 357-366;
61. b) R. D. Combes, T. Berridge, J. Connelly, M. D. Eve, R. C. Garner, S. Toon, P. Wilcox, Eur. J. Pharm. Sci. 2003, 19, 1-11;
62. c) I. R. Wilding, J. A. Bell, Drug Discovery Today 2005, 10, 890-894.
63. T. Sakamoto, F. Shiga, D. Uchiyama, Y. Kondo, H. Yamanaka, Heterocycles 1992, 33, 813-818.
64. J. Sauer, D. K. Heldmann, J. Hetzenegger, J. Krauthan, H. Sichert, J. Schuster, Eur. J. Org. Chem. 1998, 2885-2896.